Internship

Co-Op – Neuroscience

Spring 2025

Posted on 9/13/2024

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Cambridge, MA, USA

Role requires 100% onsite presence at Cambridge Crossing.

Category
Lab & Research
Life Sciences
Requirements
  • familiar with molecular biology and standard cell culture techniques
  • Experience with imaging and techniques such as western blotting, FACS, ELISAs or PCR is preferred.
Responsibilities
  • evaluate using genetic reagents and pharmacologic tools regulation of key genes driving neurodegeneration
  • carry out dose response experiments using control and candidate lead molecules
  • carry out routine cell culture
  • evaluate the effect of test small molecules in dose response reporter, mRNA and protein readouts
  • utilize microscopy to evaluate effects on neuroprotective and neuro-pathologic genes and their cellular localization and effects on cell viability.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's collaboration with AI Proteins could lead to novel miniprotein-based therapeutics.
  • The $3.5bn agreement with Prime Medicine enhances BMS's cell and gene-therapy pipeline.
  • Karen Costello's appointment may strengthen BMS's commercial strategy in Ireland.

What critics are saying

  • BMS faces legal challenges, including a lawsuit against HRSA and HHS.
  • The dismissal of a $6.4 billion lawsuit could impact BMS's financial standing.
  • Regulatory hurdles may delay the approval of new drugs, affecting market entry.

What makes Bristol-Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE